Kairos Pharma, Ltd.
KAPA · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.23 | -0.17 | -0.1 | -0.17 |
| % Growth | -35.3% | -70% | 41.2% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |